Outcome assessment of age group-specific (±50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia

Haematologica

Volumn 83, Issue 7, 1998, Pages 627-635

  Bassan, Renato ^a   Raimondi, Roberto ^b   Lerede, Teresa ^a   D'Emilio, Anna ^b   Buelli, Maurizio ^a   Borleri, Gianmaria ^a   Personeni, Alberto ^a   Bellavita, Piero ^a   Rodeghiero, Francesco ^b   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b Ospedale Civile San Bortolo   (Italy)

Author keywords

ABMT; Adult AML; High dose cytarabine

Indexed keywords

CYTARABINE; DOXORUBICIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FEMALE; HEPATOSPLENOMEGALY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PROGNOSIS; RELAPSE; REMISSION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

BONE MARROW TRANSPLANTATION; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EVALUATION STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0031927464     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Mehta J, Powles R, Singhal S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995; 16: 499-506.
2. Lowenberg B, Verdonck LJ, Dekker W, et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oncol 1990; 8:287-94.
3. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332:217-23.
4. McMillan AK, Goldstone AH, Linch DC, et al. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 1990; 76:480-8.
5. Stein AS, O'Donnell MR, Chai A, et al. In vivo purging with high-dose cytarabine followed by high-dose chemo-radiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 1996; 14:2206-16.
6. Sierra J, Brunet S, Granena A, et al. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. J Clin Oncol 1996; 14:1353-63.
7. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79:1924-30.
8. Schiller GJ, Nimer SD, Territo MC, et al. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992; 10:41-6.
9. Gale RP, Buchner T, Zhang M-J, et al. HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. Leukemia 1996; 10:1687-91.
10. Proctor SJ, Taylor PRA, Stark A, et al. Evaluation of the impact of allogeneic transplant in first remission of an unselected population of patients with acute myeloid leukemia aged 15-55 years. Leukemia 1995; 9:1246-51.
11. Reiffers J, Stoppa AM, Attal M, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996; 10:1874-82.
12. Phillips GL, Reece DE, Shepherd JD, et al. High-dose cytarabine and daunorubicin induction and post-remission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77: 1429-35.
13. Harousseau JL, Milpied N, Briere J, et al. Double intensive consolidation chemotherapy in adult acute myeloid leukemia. J Clin Oncol 1991; 9:1432-7.
14. Burke PJ, Karp JE, Geller RB, et al. Cures of leukemia with aggressive post-remission treatment: an update of timed sequential therapy (Ac-D-Ac). Leukemia 1989; 3:692-4.
15. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331:896-903.
16. Preisler HD, Raza A, Early A, et al. Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 1987; 5:722-30.
17. Wolff SN, Herzig RH, Fay JW, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 1989; 7:1260-7.
18. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87:1710-7.
19. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A southwest Oncology group study. Blood 1996; 88:2841-51.
20. Battista R, Bassan R, D'Emilio A, et al. Short-term remission induction and consolidation therapy for adult acute myelogenous leukaemia. Hematol Oncol 1991; 9:43-52.
21. Bassan R, Battista R, Viero P, et al. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. Leukemia 1995; 9:238-43.
22. Rohatiner AZS, Battista R, Bassan R, et al. Short term therapy (STT) for acute myelogenous leukaemia (AML). Leukemia 1992; 6 (Suppl 2):85-8.
23. Bennett JM, Catovsky D, Daniel M-T, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620-5.
24. Bassan R, Rambaldi A, Viero P, et al. Integrated use of morphology, cytochemistry, and immune marker analysis to identify acute leukaemia subtypes. Haematologica 1989; 74:487-90.
25. AZS Rohatiner, Bassan R, Raimondi R, et al. Myeloablative therapy with autologous bone marrow transplantation (ABMT) as consolidation of first remission in younger patients with acute myelogenous leukaemia (AML) [abstract]. Br J Haematol 1996; 93 (Suppl 2): 225. n. 848.
26. Gilmore MJML, Prentice HG, Blacklock HA, et al. A technique for rapid isolation of bone marrow mononuclear cells using Ficoll-Metrizoate and the IBM 2991 blood cell processor. Br J Haematol 1982; 50:619-26.
27. Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2:403-12.
28. Dastugue N, Payen C, Lafage-Pochilatoff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia 1995; 9:1491-8.
29. Grimwade D, Walker H, Harrison C, et al. Impact of diagnostic cytogenetics on outcome in AML: analysis of 1,613 patients entered into the UKMRC AML 10 trial [abstract]. Blood 1996; (Suppl 1):634a. n. 2525.
30. Miggiano MC, Gherlinzoni F, Rosti G, et al. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia. Leukemia 1996; 10:402-9.
31. Peto R, Pike MC, Armitage P, et al. Design of analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35:1-39.
32. te Boekhorst PAW, Lowenberg B, van Kapel J, et al. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 1995; 9:1025-31.
33. Del Poeta G, Stasi R, Aronica G, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 87:1997-2004.
34. List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87:2464-9.
35. Cahn JY, Labopin M, Mandelli F, et al. Autologous bone marrow trasplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. Blood 1995; 85:575-9.
36. Herzig RH. High-dose ara-C in older adults with acute leukemia. Leukemia 1996; 10(Suppl 1):S10-1.
37. Schiller GJ. Post-remission therapy of acute myeloid leukemia in older adults. Leukemia 1996; 10 (Suppl 1):S18-20.
38. Schiller G, Nimer S, Gajewsky J, et al. Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia: results of a randomized, controlled study. Leuk Lymphoma 1993; 11:69-77.
39. Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81:311-8.
40. Bloomfield CD, Lawrence D, Arthur DC, et al. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group [abstract]. Blood 1994; 81 (Suppl 1):111a. n. #431).
41. Bassan R, Battista R, Corneo G, et al. Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome. Leuk Lymphoma 1993; 11:105-10.
42. Weiss M, Telford P, Kempin S, et al. Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia. Leukemia 1993; 7:832-7.
43. List AF. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996; 10:937-42.
44. Preisler Hd, Raza A, Larson R, et al. Suppression of regrowth resistance and long remission durations in AML [abstract]. Blood 1996; 88(Suppl 1):218a. n. #861.
45. Perentesis JP, Kersey JH. Biologic therapy of leukemia. In: Henderson ES, Lister TA, Greaves MF. eds. Leukemia. Philadelphia: Saunders Co. 1996. p. 354-88.